Truist Securities Maintains Buy on Insulet, Lowers Price Target to $210

Benzinga Newsdesk www.benzinga.com Negative 78.3%

Neg 78.3% Neu 0% Pos 0%

Truist Securities analyst Richard Newitter maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $219 to $210.